Compare DexCom, Inc. (DXCM) vs iShares 3 7 Year Treasury Bond ETF (IEI) Price & Performance

DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.

The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.

The iShares 3-7 Year Treasury Bond ETF (IEI) trades at $116.9, showing minimal daily movement with a 0.14% gain. Technical indicators signal a bearish trend, while fundamental analysis is limited as this is a bond ETF tracking intermediate-term U.S. Treasuries. Recent news highlights investor focus on bond ETFs amid inflation concerns and Federal Reserve policy uncertainty, with comparisons to competing funds like Vanguard's VCIT and BND.

The outlook for IEI is tied to interest rate expectations and inflation trends. Opportunities include its role as a lower-volatility Treasury exposure during market uncertainty. Key risks involve potential Fed rate hikes that could pressure bond prices, competition from higher-yielding alternatives, and the narrow focus on 3-7 year maturities limiting diversification.